Technical Analysis for LNTH - Lantheus Holdings, Inc.

Grade Last Price % Change Price Change
C 86.45 8.84% 7.02
LNTH closed up 8.84 percent on Wednesday, November 20, 2024, on 2.11 times normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Flat Down Up

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 0.00%
Crossed Above 200 DMA Bullish 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
Slingshot Bearish Bearish Swing Setup 8.84%
Bullish Engulfing Bullish 8.84%
Outside Day Range Expansion 8.84%
Wide Bands Range Expansion 8.84%
Oversold Stochastic Weakness 8.84%

   Recent Intraday Alerts

Alert Time
200 DMA Resistance about 16 hours ago
Rose Above 200 DMA about 16 hours ago
60 Minute Opening Range Breakout about 17 hours ago
3x Volume Pace about 21 hours ago
Up 1 ATR about 21 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Lantheus Holdings, Inc. Description

Lantheus Holdings, Inc. is engaged in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases. The Company's medical imaging agents are used to diagnose coronary artery disease, congestive heart failure, stroke, peripheral vascular disease and other diseases. The Company's products include contrast agents and medical radiopharmaceuticals, including technetium generators. The Company's products include DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, Neurolite, Thallium Tl 201, Gallium Ga 67, Gludef, Quadramet and Ablavar. The Company is also engaged in developing agents, such as Flurpiridaz F 18, which is a myocardial perfusion imaging agent; 18F LMI 1195, which is a cardiac neuronal imaging agent, and LMI 1174, which is a vascular remodeling imaging agent.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Disease IBD 50 Chemical Elements Prostate Cancer Medical Imaging Heart Failure Stroke Medical Physics Perfusion Artery Imaging Agent Peripheral Vascular Disease Artery Disease Congestive Heart Failure Neuron Radiopharmaceuticals Coronary Artery Disease Gallium Cardiovascular And Other Diseases Medicinal Radiochemistry Myocardial Perfusion Imaging

Is LNTH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 126.8899
52 Week Low 50.2
Average Volume 961,632
200-Day Moving Average 86.16
50-Day Moving Average 103.76
20-Day Moving Average 95.68
10-Day Moving Average 82.46
Average True Range 5.32
RSI (14) 40.12
ADX 34.03
+DI 20.92
-DI 35.34
Chandelier Exit (Long, 3 ATRs) 102.26
Chandelier Exit (Short, 3 ATRs) 90.95
Upper Bollinger Bands 124.23
Lower Bollinger Band 67.13
Percent B (%b) 0.34
BandWidth 59.67
MACD Line -7.84
MACD Signal Line -6.37
MACD Histogram -1.4616
Fundamentals Value
Market Cap 5.92 Billion
Num Shares 68.5 Million
EPS 1.50
Price-to-Earnings (P/E) Ratio 57.63
Price-to-Sales 3.21
Price-to-Book 5.51
PEG Ratio 0.61
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 93.38
Resistance 3 (R3) 92.67 89.64 92.23
Resistance 2 (R2) 89.64 87.88 90.00 91.84
Resistance 1 (R1) 88.05 86.79 88.85 88.76 91.45
Pivot Point 85.02 85.02 85.42 85.38 85.02
Support 1 (S1) 83.43 83.26 84.23 84.14 81.45
Support 2 (S2) 80.40 82.17 80.76 81.06
Support 3 (S3) 78.81 80.40 80.68
Support 4 (S4) 79.52